Myaderm
Revolutionizing Pain Relief & Skin Care with CBD
Centennial, CO
Retail
We believe Myaderm is revolutionizing how you look and feel. The revolution started in 2017 with innovative cannabidiol (CBD) products that deliver effective results. Today, as a leading brand distributed coast to coast, we continue our commitment to dramatically improve how you look and feel.
$10,739
raised
15
Investors
$24.9M
Valuation
$2.00
Price per Share
$250.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
Rewards
Get rewarded for investing more into Myaderm:
$250+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Early Bird
Invest within the first two weeks and receive an additional 10% bonus shares.
2
days
13
hours
7
mins
14
secs
$250+
Investment
$250+
Advanced Therapy Fast Acting Relief Cream 1.7oz. ($49.99 retail value)
$500+
Investment
$500+
Advanced RX Fast Acting Relief Cream RX10 1.7oz. ($79.99 retail value)
$1,000+
Investment
$1,000+
3 Advanced RX Fast Acting Relief Cream RX20 1.7oz. ($299.97 retail value)
$2,000+
Investment
$2000+
3 Advanced RX Fast Acting Relief Cream RX20 1.7oz., 1 Ultimate Hydration Facial Moisturizer 1.7oz., 1 Ultimate Calming Cream 1.7oz and 1 Ultimate Wrinkle Repair 1.7oz. Set. ($374.94 retail value)
Reasons to Invest
Over three years sold coast to coast through national retailers like GNC, Rite Aid, Dick’s Sporting Goods, Golf Galaxy, 7-Eleven.
Myaderm is the only CBD brand sold through national retailers that is FDA compliant.
The US skin care market size is $18 billion and the US topical pain relief market size is $3 billion.*
*Market statistics provided by Statista (source, source)
Revolutionizing how you look and feel
Myaderm formulates, develops, manufactures, and sells skin care and pain relief products that utilize CBD as a key ingredient. We sell our products through national and local retailers, as well as directly to customers through our website. We provide products with proven pharmaceutical technologies that deliver results.
We are committed to providing the most compelling value in the market with minimized or no price friction for customers. Our mission is to revolutionize how people look and feel through the latest innovations in ingredients and technologies.
The Problem
CBD products that have low concentrations and lack technologies don’t deliver
There is a significant amount of confusion and misinformation about topical CBD products. The primary problem is with brands that rely on other well known ingredients (e.g. menthol, lidocaine) to get an effect. Those topical products also have incredibly low concentrations of CBD and lack any capable technologies (e.g. transdermal delivery, emulsification) that allow CBD to deliver results.
The Solution
Myaderm uses CBD and pharmaceutical technologies for fast acting relief and clear results
Pain Relief Competitive Advantages:
- Transdermal: drives CBD into muscle and connective tissue.
- Non-greasy and fast absorbing: other brands use oil-bases to hold CBD.
- Emulsification: high concentration of CBD in a water-bases.
- In-house formulation and manufacturing: does not utilize contract manufacturers with stock formulas.
Skin Care Competitive Advantages:
- Gel-Cream technology that is non-greasy and fast absorbing: other brands use oil-bases to hold CBD.
- Key Ingredients paired with CBD: Hyaluronic Acid, Pro-Retinol.
- Emulsification: high concentration of CBD in a water-bases.
- In-house formulation and manufacturing: does not utilize contract manufacturers with stock formulas.
INNOVATIVE
Industry leading IP and pharmaceutical technologies utilized in all products. We do not use contract manufacturers with stock formulas.
SCALABLE
Cost reduction and quality control with internal manufacturing and fulfillment expertise. We manufacture and formulate all products.
GLOBAL
FDA compliant and therapeutic products create rapid and sustainable sales.
The Market
The only CBD brand sold through national retailers that is FDA compliant
(source)
Skin care, as a market segment, is growing faster than any other part of the beauty industry. Sales of skincare products grew by 13% last year in the United States, while makeup grew by only 1% in the same period. Online beauty retailers grew 24% in that time, with skincare leading the way. (source)
Within the topical pain relief category, the rising incidences of arthritis, joint pain, and diabetic neuropathy is driving the industry growth. The growing geriatric population in the US is providing further impetus to the industry. Fewer side effects induced by topical pain relief related to oral medicine is driving the industry forward. Greater accessibility and growing awareness of topical pain medications are further aiding the industry growth.
(source)
Our Traction
Nationally distributed & selling online
Myaderm has succeeded at the national level with coast to coast sales through national retailers like GNC, Rite Aid, Dick’s Sporting Goods, Golf Galaxy, 7-Eleven.
*This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.
Code View
Offering Summary
Company | : | Myaderm, Inc. |
Corporate Address | : | 9200 E. Mineral Avenue, Ste. 355, Centennial, CO 80112 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $1,069,998.00 |
Minimum Investment Amount(per investor) | : | $250.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 5,000 |
Maximum Number of Shares Offered | : | 534,999 |
Price per Share | : | $2.00 |
Pre-Money Valuation | : | $24,883,884.00 |
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives*
Time-Based:
Early Bird
Invest within the first two weeks and receive an additional 10% bonus shares.
Amount-Based
$250+
Advanced Therapy Fast Acting Relief Cream 1.7oz. ($49.99 retail value)
$500+
Advanced RX Fast Acting Relief Cream RX10 1.7oz. ($79.99 retail value)
$1,000+
3 Advanced RX Fast Acting Relief Cream RX20 1.7oz. ($299.97 retail value)
$2,000+
3 Advanced RX Fast Acting Relief Cream RX20 1.7oz., 1 Ultimate Hydration Facial Moisturizer 1.7oz., 1 Ultimate Calming Cream 1.7oz and 1 Ultimate Wrinkle Repair 1.7oz. Set. ($374.94 retail value)
$5,000+
10 Products of choice (up to $999.99 retail value)
$10,000+
20 Products of choice (up to $1,999.80 retail value)
*All perks occur when the offering is completed.
The 10% StartEngine OWNers' Bonus
Myaderm will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $200. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus.
The Company will not incur any irregular use of proceeds.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$2,787,567.00
USD
$3,057,868.00
USD
Cash And Cash Equivalents
$137,128.00
USD
$42,856.00
USD
Accounts Receivable
$548,806.00
USD
$662,280.00
USD
Short Term Debt
$196,431.00
USD
$874,582.00
USD
Long Term Debt
$1,645,262.00
USD
$1,620,230.00
USD
Revenues And Sales
$1,748,679.00
USD
$1,787,846.00
USD
Costs Of Goods Sold
$391,166.00
USD
$515,391.00
USD
Taxes Paid
-$77,365.00
USD
$418,920.00
USD
Net Income
$382,820.00
USD
-$1,137,224.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Let Us Know What You Think
1 day agoMyaderm has deals on the table with a Major League Baseball team and the recently formed Major League Rugby. Would love to hear from investors and anyone interested in Myaderm which sounds more compelling and interesting. Should we partner with one or the other or both? This is one example of why we are raising capital!
Only five days left for our Early Bird Offer
2 days agoWhy not earn an extra 10% of shares? Why wait on the sidelines? Invest now and earn an extra 10%. This offer will expire on Tuesday morning 10AM eastern time.
Myaderm, a Market Leader in CBD Products, Raising Capital to Drive Growth Through StartEngine Launch
8 days ago
Welcome Myaderm Investors
9 days agoWe are excited for you to become an investor in Myaderm and part of the team! Over the past four years we’ve disrupted the topical relief and skin care markets using CBD as a key ingredient. Myaderm is now raising capital to drive growth and market leadership. We make innovative products that use proven pharmaceutical technologies to deliver results. Our mission is clear: revolutionize how you look and feel. - Eric Smart, CEO and Founder of Myaderm.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}